These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11474317)

  • 1. Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients.
    Beurton I; Bertrand MA; Bresson-Hadni S; Parquet-Gernez A; Goudemand J; Paris JC; Cales P; Briquel ME; Gaucher P; Cortey ML; Trepo C; Miguet JP; Cahn JY
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):859-64. PubMed ID: 11474317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment.
    Franchini M; Tagliaferri A; Rossetti G; Capra F; Veneri D; de Maria E; Pattacini C; Aprili G; Gandini G
    Haemophilia; 2002 Nov; 8(6):794-7. PubMed ID: 12410649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.
    Kevans D; Farrell G; Hopkins S; Mahmud N; White B; Norris S; Bergin C
    Haemophilia; 2007 Sep; 13(5):593-8. PubMed ID: 17880449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
    Buti M; Olive G; Stalgis C; Esteban R; Guardi J
    Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mild chronic hepatitis C with interferon alpha-2b: results of a multi-centre randomized study in 80 patients.
    Queneau PE; Osaer F; Bronowicki JP; Monnot B; Thiefin G; Bettinger D; Carbillet JP; Raabe JJ; Fratte S; Minello-Franza A; Bresson-Hadni S; Miguet JP
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):143-7. PubMed ID: 11246613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
    Nasti G; Di Gennaro G; Tavio M; Cadorin L; Tedeschi RM; Talamini R; Carbone A; Tirelli U
    AIDS; 2001 Sep; 15(14):1783-7. PubMed ID: 11579239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
    Barbaro G; Barbarini G
    Eur J Gastroenterol Hepatol; 2002 May; 14(5):477-83. PubMed ID: 11984144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha treatment of chronic hepatitis C in children with hemophilia.
    Ko JS; Choe YH; Kim EJ; Lee EH; Jang JJ; Seo JK
    J Pediatr Gastroenterol Nutr; 2001 Jan; 32(1):41-4. PubMed ID: 11176323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs.
    Hayashi K; Fukuda Y; Nakano I; Katano Y; Yokozaki S; Toyoda H; Takamatsu J; Hayakawa T
    Haemophilia; 2000 Nov; 6(6):677-81. PubMed ID: 11122395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
    Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
    J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
    Brillanti S; Foli M; Di Tomaso M; Gramantieri L; Masci C; Bolondi L
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):130-4. PubMed ID: 10363198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.